ArticleScientific reports2025
Tumor behavior disparities in all-cause and cause-specific mortality among patients with central nervous system tumors.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The tumor behavior disparities (nonmalignant vs. malignant) in all-cause and cause-specific mortality among patients with central nervous system (CNS) tumors have not been investigated. In this study, a total of 324,817 US patients with CNS tumors (including 207,273 nonmalignant tumors and 117,544 malignant tumors) were enrolled from the SEER database (SEER-17; 2000-2021). Among all patients, 23.70% died from primary tumors, and 18.52% died from competing risk events. Among all competing event deaths, cardiovascular disease (CVD) death (27.32%) was the most common cause of death. Compared with patients with nonmalignant tumors, patients with malignant tumors had a significantly greater proportion of all-cause deaths (70.73% vs. 26.05%) and primary tumor deaths (61.48% vs. 2.28%), whereas they had a lower proportion of competing event deaths (9.25% vs. 23.77%). Among patients with nonmalignant tumors, all-cause deaths were attributed mainly to competitive risk deaths. In contrast, all-cause deaths were attributed mainly to primary tumor deaths among patients with malignant tumors. The patients with malignant tumors had higher risks of all-cause mortality (HR = 5.4, 95% CI: 5.32-5.48, P < 0.001), primary tumor mortality (HR = 47.3, 95% CI: 45.8-48.9, P < 0.001), and competing event mortality (HR = 1.05, 95% CI: 1.02-1.08, P < 0.001) compared to those with non-malignant tumors, respectively. The all-cause and cause-specific mortality for causes of death (COD) varied by tumor behavior and tumor type. This study investigated the tumor behavior disparities in all-cause and cause-specific mortality via a larger population-based cohort, and it provided robust evidence for an in-depth understanding of the tumor behavior disparities in cumulative mortality among patients with CNS tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.